FIELD: medicine.
SUBSTANCE: invention refers to medicine and biotechnology. Disclosed is a method for producing a bruclease antigen. Method involves cultivation of Brucella abortus 19 BA on a dense nutrient medium followed by water-salt extraction with 2.5 % NaCl 1:1 solution for one day, destruction of microbial cells on a hydraulic press, centrifugation and lyophilization of the supernatant.
EFFECT: invention provides staging of antigen-stimulated cell responses in vitro for assessing the formation of postvaccinal immunity against the brucellosis agent.
1 cl, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING ACTUAL VACCINATION OF PEOPLE AGAINST BRUCELLOSIS IN THE EARLY STAGES AFTER VACCINATION | 2019 |
|
RU2714136C1 |
| METHOD FOR ASSESSING PROTECTIVE IMMUNITY AGAINST CAUSATIVE AGENT OF BRUCELLOSIS | 2022 |
|
RU2806161C1 |
| METHOD FOR ASSESSING POSTVACCINAL IMMUNITY AGAINST BRUCELLOSIS | 2019 |
|
RU2740009C1 |
| METHOD FOR IMMUNOLOGICAL DIAGNOSIS OF BRUCELLOSIS | 2022 |
|
RU2785906C1 |
| METHOD OF USING COMPLEX OF WATER-SOLUBLE ANTIGENS OF PLAGUE MICROBE FOR EVALUATION OF ANTIPLAGUE IMMUNITY LEVEL | 2019 |
|
RU2725872C1 |
| STRAIN OF F26 OF CONSTANT MONOCLONAL ANTIBODY LINE OF CELLS OF MUS MUSCULUS MOUSE - PRODUCER OF MONOCLONAL ANTIBODIES TO OLIGOPOLYSACCHARIDE (OPS) ANTIGEN B ABORTUS | 2014 |
|
RU2560260C1 |
| POLYVALENT CORPUSCULAR ANTIGEN FOR PRODUCTION OF MEDICAL AND PREVENTIVE BIOLOGICAL PRODUCTS FOR BRUCELLOSIS | 2006 |
|
RU2330681C1 |
| METHOD FOR DIFFERENTIATING IN VITRO POSTVACCINAL AND INFECTIOUS BRUCELLOSIS ACCORDING TO DEGREE OF BODY HYPERSENSITIVITY TO BRUCELLA | 2015 |
|
RU2574207C1 |
| METHOD FOR EVALUATING LYMPHOCYTE BLAST-TRANSFORMATION REACTION BY FLOW CYTOMETRY AT SPECIFIC ACTIVATION BY ANTIGEN | 2015 |
|
RU2582395C1 |
| MOLECULAR VACCINE FOR BRUCELLOSIS PROPHYLAXIS | 2003 |
|
RU2285538C2 |
